IKT compared with LONA: revenue, margins and what each company keeps, and the suppliers and customers both name

IKTInhibikase Therapeutics, Inc.

Mkt capRevenueRevenue

LONALeonaBio, Inc.

Mkt capRevenueRevenue

Compare

IKTInhibikase Therapeutics, Inc.

LONALeonaBio, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

IKT: latest quarter is a loss; flow not drawable. LONA: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only IKT 0

None

Shared 0

No disclosed counterparties: IKT.

Only LONA 6

LGNDLigand Pharmaceuticalssupplier

—AnswerALS consortiumunlistedsupplier

—Sermonixunlistedsupplier

—Sermonix Pharmaceuticalsunlistedsupplier

2 more · LONA chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

Price

rebased to 0%

IKT, solidLONA, dashed

IKTInhibikase Therapeutics, Inc.

1.55· pre 1.53· delayed

Mkt cap$216.3MRevenue$79,569Q3 FY23

LONALeonaBio, Inc.

4.80· pre 4.80· delayed

Pre-marketOct 30 '26delayed

Mkt cap$46.5MRevenue—

Compare

Pre-marketOct 30 '26delayed

IKTInhibikase Therapeutics, Inc.

LONALeonaBio, Inc.

1.55pre 1.53delayed

Price

4.80pre 4.80delayed

$216.3M

Mkt cap

$46.5M

Q3 FY23$79,569

Revenue

—

IKT1.55vsLONA4.80Pre-marketOct 30 '26delayed